Treatment of respiratory syncytial virus with palivizumab in an adult liver transplant recipient: a case report

Keyphrases

• Liver Transplant Recipients 100%
• Respiratory Syncytial Virus 100%
• Palivizumab 100%
• Immunocompromised Patients 28%
• Liver Transplantation 14%
• Conventional Treatment 14%
• Young Female 14%
• Monoclonal Antibody 14%
• Intensive Care Unit 14%
• Adult Patients 14%
• Orthotopic Liver Transplantation 14%
• Extubated 14%
• Upper Respiratory Tract Infection 14%
• 50 Years Old 14%
• Supportive Care 14%
• Lower Respiratory Tract Infection 14%
• Intravenous Corticosteroids 14%
• Cough 14%
• Off-label Use 14%
• Intramuscularly 14%
• Shortness of Breath 14%
• Salvage Therapy 14%
• Cost Savings 14%
• Alternative Regimens 14%
• Acute Hypoxemic Respiratory Failure 14%
• Immunocompromised Adults 14%
• Oral Ribavirin 14%
• Respiratory Panel 14%
• Emergent Intubation 14%

Medicine and Dentistry

• Liver Graft 100%
• Human respiratory syncytial virus 100%
• Palivizumab 100%
• Immunocompromised Patient 28%
• Health Care Cost 14%
• Dyspnea 14%
• Monoclonal Antibody 14%
• Intensive Care Unit 14%
• Low Drug Dose 14%
• Coughing 14%
• Intubation 14%
• Upper Respiratory Tract Infection 14%
• Ribavirin 14%
• Supportive Care 14%
• Respiratory Failure 14%
• Salvage Therapy 14%
• Off-Label Use 14%
• Lower Respiratory Tract Infection 14%
• Patient History of Liver Transplantation 14%
• Oral 14%